Breakout Stocks   Corona Virus Stocks 


Maxim Research Says $4.00 Price Target

  CEO Webinar – CEO Red Chip Research Interview

Recently a 26 year old woman died from a botched epidural in a New York City hospital . For years doctors have been confronted with the not so easy task of finding that space in the spine between the supporting bones and the actual chord fluid channel . A bad epidural procedure can put the patients life in danger .

Watch This You Tube Video Interview On Cather Placement In The Spine

Milestone Scientific Inc
 has developed and patented the CompuFlo Epidural Instrument which senses pressure at the needle tip either warning the doctor he has chosen the wrong injection point or allowing the doctor to proceed . This instrument detects subtle pressure changes 4 times a second making it extremely responsive to minor pressure changes allowing the doctor to find that soft space between the bones and muscle.

Added To Russell 3000 ( R )  – MLSS NASDAQ – Biomed-Technology -Soars Into Action

Future uses of this medical device include

  Cosmetic Surgery
  Ophthalmic Injections
  Neurosurgical Injections
  Self Administered Injections
  General Medical Injections
  Intra-Articular Injections
This company is at the forefront of medical technology. Recently added to the Russell 3000 and Russell Microcap and raised $14.6 Million through a stock and warrant offering Maxim Group This company is well funded into the future .

Maxim Group places a $4.00 price target on these shares We urge serious investors to place these shares on their BUY LIST. Any move above  the $2.25 level sends these shares into BREAKOUT TERRITORY.


News and Media

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. We have been paid 10,000 shares for 6 months by the company  Please consult with an independent investment adviser and qualified investment professional before making an investment decision.